Phase II trial of APL-1202 in patients with high risk non-muscle-invasive bladder cancer patients
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs APL 1202 (Primary)
- Indications Bladder cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Asieris Pharmaceuticals
- 27 Dec 2017 Status changed from active, no longer recruiting to completed according to an Asieris Pharmaceuticals media release.
- 27 Dec 2017 According to an Asieris Pharmaceuticals media release, results from this trial have been presented at the 2017 Bladder Cancer Research Symposium organized by the Albert Institute and MD Anderson Cancer Center, and at the 2017 Annual Meeting of Chinese Society of Clinical oncology (CSCO).
- 03 Mar 2016 New trial record